Xylamidor 20 mg/ml Injektionslösung für Tiere

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:
Xylamidor 20 mg/ml Injektionslösung für Tiere
Xylamidor 20 mg/ml injeksjonsvæske, oppløsning til storfe, hest, hund og katt

Active substance:
Xylazine hydrochloride

Target species:
Cattle
Dog
Cat
Horse

Route of administration:
Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:

Xylazine hydrochloride
23.32 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Meat and offal. 1 day
  - Milk. 0 hour

Intravenous use:

- **Cattle**
  - Meat and offal. 1 day
  - Milk. 0 hour

- **Horse**
  - Meat and offal. 1 day
  - Milk. 0 hour

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN05CM92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Norway

Available in:
Norway

Package description:
Clear glass vial type I with 5 x 10 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap in a cardboard box.
Clear glass vial type II with 25 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.
Clear glass vial type II with 50 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.
Clear glass vial type I with 10 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Vetviva Richter GmbH

Marketing authorisation date:
5/07/2023

Manufacturing sites for batch release:
Vetviva Richter GmbH

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
22-14676

Date of authorisation status change:
5/07/2023

Reference member state:
Austria

Procedure number:
AT/V/0029/001

Concerned member states:
Belgium Bulgaria Cyprus Denmark Finland France Germany Greece Ireland Italy Latvia Netherlands Norway Poland Romania Slovakia Slovenia Spain Sweden

Generic of:
600000072350

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.